GlassScriptPhysician profile
J Leonard Dire
NPI 1588639389
$823.85
in general payments reported to CMS, 2019-2025
16 companies · $37.67 in 2025
The $37.67 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $68.64 · 2023: $44.55 · 2024: $148 · 2025: $37.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $230.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $269.04 | 2019-2020 | |
| Biotronik INC. | $133.15 | 2024 | Acticor 7 Vr-T Dx |
| Sanofi-Aventis U.S. LLC | $62.15 | 2019-2020 | |
| Gilead Sciences, INC. | $52.47 | 2019 | |
| Abiomed | $44.55 | 2023 | Impella |
| E.R. Squibb & Sons, L.L.C. | $37.59 | 2019-2024 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $35.12 | 2019 | |
| Pfizer INC. | $32.98 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.21 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.91 | 2019 | |
| Boston Scientific Corporation | $21.58 | 2019 | |
| Novo Nordisk INC | $21.26 | 2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $19.10 | 2019 | |
| Abbott Laboratories | $17.88 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.41 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $12.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw J Leonard Dire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.